pargyline has been researched along with imidazole in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dethe, DH; Ranjan, A; Wakchaure, PB; Yerande, R; Yerande, SG | 1 |
| Dong, SN; Gong, Q; Li, J; Li, XK; Liu, WW; Mao, F; Tang, Y; Wang, H; Wang, TD; Xu, YX; Zhang, HY; Zhu, J | 1 |
2 other study(ies) available for pargyline and imidazole
| Article | Year |
|---|---|
Base-mediated hydroamination of propargylamine: a regioselective intramolecular 5-exo-dig cycloisomerization en route to imidazole-2-thione.
Topics: Catalysis; Cyclization; Ethylenethiourea; Gold; Imidazoles; Molecular Structure; Pargyline; Propylamines; Stereoisomerism; Thiones; Transition Elements | 2014 |
Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognitive Dysfunction; Dose-Response Relationship, Drug; Drug Discovery; Humans; Imidazoles; Mice; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Propylamines; Pyrimidines; Rats; Scopolamine; Structure-Activity Relationship; Thiourea | 2018 |